Lupin Limited (BOM:500257)
India · Delayed Price · Currency is INR 1,893.10
-9.35 (-0.49%)
At close: Aug 29, 2025
Lupin Revenue
Lupin had revenue of 62.68B INR in the quarter ending June 30, 2025, with 11.93% growth. This brings the company's revenue in the last twelve months to 233.76B, up 12.40% year-over-year. In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B with 13.48% growth.
Revenue (ttm)
233.76B
Revenue Growth
+12.40%
P/S Ratio
3.70
Revenue / Employee
9.74M
Employees
24,006
Market Cap
864.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Hindustan Unilever | 639.28B |
| Infosys | 1,672.76B |
Lupin News
- 11 days ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 11 days ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 19 days ago - Lupin partners with Sandoz to commercialize Ranibizumab biosimilar in multiple global markets - Business Upturn
- 20 days ago - Lupin launches Glucagon for Injection in the U.S. market - Business Upturn
- 6 weeks ago - Lupin’s Pithampur Unit-3 gets 3 observations from US FDA after inspection - Business Upturn
- 6 weeks ago - Lupin launches generic Lotemax ophthalmic suspension in the U.S. market - Business Upturn
- 2 months ago - Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market - Business Upturn
- 2 months ago - Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel; Eligible for 180-day generic exclusivity - Business Upturn